Quantcast
Last updated on April 16, 2014 at 4:43 EDT

Latest Mapatumumab Stories

2013-09-30 13:15:10

New results from a trial of an antibody that helps the immune system to recognize and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers. Presenting the most up-to-date data from 85 patients with non-small cell lung cancer in a large, phase I clinical trial of an experimental drug called MPDL3280A, Professor Jean-Charles Soria told the 2013 European Cancer Congress (ECC2013) today (Sunday): "This is the first study to suggest a...

2013-09-04 08:30:38

-- Phase I/II study showed the addition of NovoTTF Therapy to pemetrexed is safe and potentially more effective than pemetrexed alone for second line NSCLC ST. HELIER, Jersey, Sept. 4, 2013 /PRNewswire/ -- Results of the first clinical trial to study treatment with tumor treating field therapy (NovoTTF Therapy) in combination with chemotherapy for patients with non-small cell lung cancer (NSCLC) were published in the journal Lung Cancer. The study demonstrated that combining NovoTTF...

2013-08-01 08:32:15

The ORCA(TM) Program Continues to Expand with Patient Enrollment Now Open for First Phase 2 Trial of OGX-427 in Non-Small Cell Lung Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 1, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Spruce(TM) clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 trial evaluating OGX-427, a heat shock protein 27 (Hsp27) inhibitor, in patients...

2013-05-23 08:26:41

OGX-427 ORCA(TM) Program Expands to Include Second Phase 2 Trial in Patients with Advanced Lung Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, May 23, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar(TM) clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial will be the...

2013-03-22 08:24:51

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire/ -- Cerulean Pharma Inc. today announced that a randomized Phase 2b study of its experimental cancer treatment, CRLX101, in patients with advanced non-small cell lung cancer (NSCLC) did not meet its primary efficacy endpoint, overall survival benefit. Consistent with earlier clinical trials, CRLX101 showed signals of activity, including tumor reductions that meet RECIST criteria, and a favorable safety profile. CRLX101 is being studied in four...

2012-12-19 08:24:43

Company to Hold Conference Call at 8:30 am EST Today SEATTLE, WA, Dec. 19, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that the pivotal Phase 3 clinical trial of L-BLP25 (formerly referred to as Stimuvax(®)) known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer (NSCLC).  The trial was conducted by Merck Serono, a...

2012-06-20 02:26:31

CALGARY, June 20, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) NASDAQ: ONCY) announced today that the Company's independent Data Monitoring Committee (DMC) has reviewed the safety data for the first stage of its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers (REO 018). Based on the review of the safety data the DMC has recommended that enrollment continue in the study. "The safety data...

2012-06-05 02:27:45

--Company to Host Conference Call to Discuss Randomized Phase II Program-- CALGARY, June 5, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic non-small cell lung cancer ("NSCLC"). "This agreement...

2012-06-04 02:26:56

SAN DIEGO, June 4, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced results from a Phase I clinical trial of its lead drug candidate ME-143 in patients with solid refractory tumors. The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago today. "We are encouraged by the results from this first-in-human study of ME-143,"...

2012-05-29 02:27:26

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors. The dose escalation trial is expected to enroll up to 24 patients in up to five cohorts with final safety...